Source: International Congress 2018 – Lung cancer Grand Round
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Frille (Leipzig, Germany). Intercalating multimodal treatment strategy in a patient with advanced pulmonary adenocarcinoma harbouring the uncommon complex EGFR mutation L833V/H835L. International Congress 2018 – Lung cancer Grand Round

Member's Comments

No comment yet.

Related content which might interest you: Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Prognosis of uncommon metastasis in non-small-cell lung cancer patients with mutated EGFR Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009 Successful targeted therapy of advanced lung cancer Source: Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session Year: 2013 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 The features of rare pulmonary tumors and their surgical treatment Source: Virtual Congress 2020 – Thoracic surgery: lung cancer and infectious disease Year: 2020 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019 Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease Source: Eur Respir J, 50 (4) 1701658; 10.1183/13993003.01658-2017 Year: 2017 Treatment landscape in oncogene driven advanced NSCLC Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 A new treatment strategy for stage III lung cancer presenting with airway obstruction: neoadjuvant endobronchial intratumoral chemotherapy (EITC) Source: Annual Congress 2009 - Biopsy techniques Year: 2009 Endobronchial intratumoral chemotherapy followed by surgery in early non-small-cell lung cancer with polypoid growth erroneously diagnosed as an advanced disease Source: Eur Respir J 2006; 28: Suppl. 50, 610s Year: 2006 Symptomatic benefit of short regimen of palliative radiotherapy for elderly patients with locally advanced non small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017 Year: 2018 KRAS oncogene in lung cancer: focus on molecularly driven clinical trials Source: Eur Respir Rev 2015; 25: 71-76 Year: 2016 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the thoracic surgeon Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007